Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | -0.59% | +1.35% | +18.59% |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
May. 13 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- MRK Stock
- Revisions Merck & Co., Inc.